Grail Inc
NASDAQGS:GRAL
United States / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
31.76 USD
Day change
1.47 (4.85%)
52-week range
12.33 - 63.99
9:39 PM - Real Time Data
Summary of Grail Inc
Hide this widget
GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internation...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Years
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| GRAL | Peers | Sector | |
|---|---|---|---|
Market Cap | 1.027 B | 64.481 M | 66.257 M |
Price % of 52 Week High | 49.4% | 50.6% | 62.8% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | 1.6% | -21.7% | -0.7% |
1 Year Price Total Return | 121.7% | -10.7% | -11.0% |
Beta (5 Year) | - | 0.92 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for Grail is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for Grail Inc
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 1 day ago |
| Earnings Power ValueView Updated 4 hours ago |
| 10Y Historical FinancialsView Updated 1 day ago |
| 5Y Historical FinancialsView Updated 1 day ago |
| EV / EBIT MultiplesView Updated 4 hours ago |
| EV / EBITDA MultiplesView Updated 4 hours ago |
| P/E MultiplesView Updated 4 hours ago |
| Price / Book MultiplesView Updated 4 hours ago |
| Price / Sales MultiplesView Updated 4 hours ago |
| EV / Revenue MultiplesView Updated 4 hours ago |
| CAPM WACC ModelView Updated 1 hour ago |
Historical Financials
Full Financials
Hide this widget
| (USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Jan-23 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 56 | 93 | 126 | 30 | 38 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | |||||
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 96 | 84 | 68 | 84 | 68 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (584) | (609) | (582) | (133) | (94) |
Analyst Notes
March 24, 2025
Hide this widget